Related Experiment Video
Updated: Jan 21, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
FRK suppresses human glioma growth by inhibiting ITGB1/FAK signaling
Jun Wang1, Chang Cai2, Dekang Nie3
1Institute of Nervous System Diseases, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou, 221002, Jiangsu, PR China; Department of Neurosurgery, The First People's Hospital of Yancheng, The Forth Affiliated Hospital of Nantong University, Yancheng, 224006, Jiangsu, PR China.
Abstract:
Fyn-related kinase (FRK), a member of the Src-related tyrosine kinase family, functions as a tumor suppressor in several malignancies. We previously showed that FRK overexpression inhibited the growth of glioma cells. However, it is unknown whether FRK is equally effective against intracranial glioma in vivo, and the mechanism by which FRK influences glioma cell growth remains unclear. In this study, we found that tumor volume was reduced by about one-third in mice with FRK overexpression, which showed improved survival relative to controls. Immunofluorescence analysis revealed that FRK overexpression inhibited glioma cell proliferation and induced their apoptosis. Importantly, in vitro we further found that FRK decreased the expression of integrin subunit β1 (ITGB1) at both the mRNA and protein levels. FRK also inhibited transactivation by ITGB1, resulting in the suppression of its target proteins AKT and focal adhesion kinase (FAK). ITGB1 overexpression promoted glioma cell growth and partially reduced FRK-induced growth suppression. These results indicate that FRK inhibits human glioma growth via regulating ITGB1/FAK signaling and provide a potential therapeutic target for the treatment of glioma.
Insights
Fyn-related kinase (FRK) suppresses glioma growth in vivo by inhibiting integrin subunit β1 (ITGB1) signaling. This discovery offers a potential therapeutic strategy for glioma treatment.
Area of Science:
- Molecular Oncology
- Cancer Biology
- Neuro-oncology
Background:
- Fyn-related kinase (FRK), a Src-related tyrosine kinase, acts as a tumor suppressor in various cancers.
- Previous studies indicated FRK overexpression inhibits glioma cell growth in vitro.
- The in vivo efficacy and precise mechanism of FRK in intracranial glioma remained unelucidated.
Purpose of the Study:
- To investigate the in vivo effectiveness of FRK in suppressing intracranial glioma growth.
- To elucidate the molecular mechanism underlying FRK's influence on glioma progression.
Main Methods:
- FRK overexpression in glioma cells and subsequent implantation in mice to assess tumor growth and survival.
- Immunofluorescence analysis to evaluate glioma cell proliferation and apoptosis.
- In vitro studies to determine FRK's effect on integrin subunit β1 (ITGB1) expression and downstream signaling pathways (AKT, FAK).
Main Results:
- FRK overexpression significantly reduced tumor volume by approximately one-third and improved survival in mice.
- FRK inhibited glioma cell proliferation and induced apoptosis.
- FRK decreased ITGB1 mRNA and protein levels, suppressed ITGB1 transactivation, and inhibited AKT and FAK signaling.
Conclusions:
- FRK effectively inhibits human glioma growth in vivo.
- FRK exerts its tumor-suppressive effects by regulating the ITGB1/FAK signaling pathway.
- FRK represents a promising therapeutic target for glioma treatment.
More Related Videos
Related Concept Videos
Feedback Inhibition
Primary and Secondary Growth in Roots and Shoots
Enzyme Inhibition
Population Growth
Inhibition of Cdk Activity
What is Cell Signaling?

